Journal of the International Association of Providers of AIDS Care (Jan 2019)

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

  • Oche O. Agbaji MBBS,
  • Isaac O. Abah B.Pharm, MPH,
  • Augustine O. Ebonyi MBBS, MSc,
  • Zumnan M. Gimba MBBS,
  • Esla E. Abene MBBS,
  • Simji S. Gomerep MBBS,
  • Kakjing D. Falang PhD,
  • Joseph Anejo-Okopi PhD,
  • Patricia A. Agaba MBBS,
  • Placid O. Ugoagwu BSc,
  • Emmanuel I. Agaba MBBS,
  • Godwin E. Imade PhD,
  • Atiene S. Sagay MBBS,
  • Prosper Okonkwo MBBS,
  • John A. Idoko MBBS,
  • Phyllis J. Kanki DVM, DSc

DOI
https://doi.org/10.1177/2325958218821963
Journal volume & issue
Vol. 18

Abstract

Read online

Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART). Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34). Conclusion: Long-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDF-based regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide–based regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries.